



A new rapid detection tool against high-risk HPV

We are glad to announce that GeneMe was granted in the 4th edition of the Polish Challenge Fund. The competition involved companies from Poland and local partners from Moldova, Ukraine, and Georgia. Successfully, GeneMe got a valuable partner from Georgia, which is the Georgian Organization of Cancer Research (GOCR). For the next 6 months, we will cooperate till the implementation of our rapid HPV detection technology in the Georgian market.

Until now, diagnosis of HPV is done by two-step testing. First, the belonging to a given group of HPV strains is tested, and then the dedicated test is carried out in terms of belonging to a given strain. Currently, 15 high-risk HPV strains of carcinogenic importance have been selected. However, high-sensitivity laboratory tests have very long and expensive procedures. Due to this fact, the prevention of HPV infections is difficult and inaccessible to everyone, the same trend is also observed in Georgia. GeneMe plans to implement a rapid point-of-care diagnostic test at a local partner, which will significantly speed up screening tests in gynecology and urology offices.

GeneMe was one of the first companies in Poland to introduce tests for COVID-19 diagnostics. It was possible thanks to the experience we have gained by carrying out genetic tests on disease risks and predispositions. We have also noticed the need for much faster and more efficient diagnostics also in the segment of diagnostics of infectious diseases. Thanks to participation in the Polish Challenge Fund, we managed to establish cooperation with GOCR, therefore we will be able to develop quick tests for the diagnosis of HPV infections in Georgia and we will significantly contribute to increasing the detection of high-risk HPV. The final success of these tests is significantly influenced by the development of innovative enzyme production technologies and their effective lyophilization, thanks to which they can be easily stored and transported – Kasjan Szemiako, CTO, Geneme Sp. z o.o.

Approximately 330 cases of HVP-related cervical cancer are identified in Georgia each year, making it the 5th cancer incidence rate in women. For these reasons, it is necessary to search for and introduce tools for the effective diagnosis of human papillomavirus infection and early neoplastic lesions in the oropharynx. There are currently solutions on the market that allow the identification of HPV, but they are characterized by difficulties in preparation and a long waiting time for the result. We think creating a fast and effective test for PCR technology in collaboration with GeneMe, will significantly help physicians to identify carcinogenic HPV strains in potentially infected individuals.

We work closely with all oncology profiles hospitals and non-governmental organizations in Georgia, as well as we are involved in municipal programs. We believe that the promotion of the screening project is a priority, which on the one hand affects the quality of life of the patient and on the other hand the development of effective medical services. We stay strongly committed to cancer patients, maintain an oncology profile, and strive to implement new diagnostic solutions for patients in need. Collaboration with our foreign partners is a great opportunity for us - sated Ms, Tamar Javakhadze, GOCR.

"The project 'An Innovative PCR Test to Rapid Detection of 15 High-Risk HPV Strains' is implemented by the United Nations Development Programme (UNDP) through the Polish Challenge Fund, with the financial

support of the Ministry of Foreign Affairs of the Republic of Poland. The Polish Challenge Fund is a component of the "Polish-UNDP Partnership: Innovative Solutions for the SDGs", a Project financed by the Ministry of Foreign Affairs of the Republic of Poland and implemented by the UNDP Istanbul Regional Hub."

An innovative PCR test to rapid detection of 15 high-risk HPV strains

According to WHO data, 10-20% of people aged 15-49 are infected with HPV worldwide, including almost 40% of women under 25 years of age. Approximately 330 cases of HVP-related cervical cancer are identified in Georgia each year, making it the 5th cancer incidence rate in women. Only about 20% of women under the age of 15 receive full vaccination. Thus, despite the unquestionable importance of HPV-dependent cancer prophylaxis by vaccination, it is not sufficient. For these reasons, it is necessary to search for and introduce tools for effective diagnosis of human papillomavirus infection and early neoplastic lesions in the oropharynx. GeneMe intends to develop an innovative, fast and accurate test to identify carcinogenic HPV strains in potentially infected individuals.

Georgia, 2022

40 000 USD

Contacts

GeneMe Sp. z o.o.

Karol Leśniewicz, kontakt@geneme.eu, +48 517 169 126

Tomasz Pawlikowski, projekty@ibmm.pl, +48 781 052 255

Georgian Organization of Cancer Research

Mamuka Khvedelidze, m.khvedeli@gmail.com, +995 599 49 20 98

Tamar Javakhadze, tamar_javakhadze@hotmail.com, info@gocr.ge, +995 599 56 09 40

UNDP – Polish Challenge Fund

Magdalena Kudlicka, magdalena.kudlicka@undp.org, +48 795 550 628